Skip to main content
Premium Trial:

Request an Annual Quote

VigeneTech, CapitalBio to Integrate Protein Array, Image Analysis Technologies

NEW YORK (GenomeWeb News) – Imaging data analysis developer VigeneTech said today that it has formed a partnership with Chinese biochip maker CapitalBio to develop protein array analysis solutions.
 
Under the agreement, the companies will integrate VigeneTech’s OEM software with CapitalBio’s LuxScan microarray scanners to market “fully integrated and personalized solutions,” CapitalBio said in a statement.
 
The first OEM products under the agreement will be developed around VigeneTech’s MicroVigene microarray image analysis software, and the hardware control component will be embedded in the MicroVigene protein array analysis suite. The firms believe it will “fulfill all of the demands of high quality and high throughput needed for array applications in all areas of clinical diagnostics and life science research.”
 
Financial terms of the alliance were not disclosed.
 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.